Thursday, June 1, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Medicine and Medical Director
Comprehensive Cancer Center Ulm (CCCU)
Head, Early Clinical Trials Unit (ECTU)
Head, Division of CLL Dept. of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
Ulm, Germany
Consultant Hematologist
Oxford Cancer and Haematology Centre
Churchill Hospital
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Professor of Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.75 ABIM MOC points
This activity is intended for hematology/oncology specialists and pathologists.
The goal of this activity is for learners to be better able to understand the latest data related to the use of Bruton tyrosine kinase (BTK) inhibitor (BTKi) therapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL), and the implications for current and future clinical practice.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
Professor of Medicine and Medical Director
Comprehensive Cancer Center Ulm (CCCU)
Head, Early Clinical Trials Unit (ECTU)
Head, Division of CLL Dept. of Internal Medicine III
Comprehensive Cancer Center Ulm (CCCU)
Ulm, Germany
Consultant Hematologist
Oxford Cancer and Haematology Centre
Churchill Hospital
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Professor of Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Developed through a collaboration between Medscape Oncology and The Leukemia & Lymphoma Society (LLS).
Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 3/21/2023
Valid for credit through: 3/21/2024
processing....
Download the pdf.
| « Return to: BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients |
